Skin Cancer Diagnostics & Therapeutics Market Report: Trends, Forecast and Competitive Analysis to 2030

Skin Cancer Diagnostics & Therapeutics Trends and Forecast

The future of the global skin cancer diagnostics & therapeutics market looks promising with opportunities in the diagnosis and therapeutic markets. The global skin cancer diagnostics & therapeutics market is expected to reach an estimated $18.1 billion by 2030 with a CAGR of 5.0% from 2024 to 2030. The major drivers for this market are increasing government initiatives for early detection and skin cancer treatment, rising research and development activities for skin cancer diagnostics and therapeutics, and growing incidences and rising awareness of skin cancer globally.

A more than 150-page report is developed to help in your business decisions.

Skin Cancer Diagnostics & Therapeutics by Segment

The study includes a forecast for the global skin cancer diagnostics & therapeutics by cancer type, type, and region.

Skin Cancer Diagnostics & Therapeutics Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:

• Melanoma
• Non-Melanoma

Skin Cancer Diagnostics & Therapeutics Market by Type [Shipment Analysis by Value from 2018 to 2030]:

• Diagnosis
• Therapeutics
• Others

Skin Cancer Diagnostics & Therapeutics Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Skin Cancer Diagnostics & Therapeutics Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies skin cancer diagnostics & therapeutics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the skin cancer diagnostics & therapeutics companies profiled in this report include-

• Ab Science
• Abbott Laboratories
• Amgen
• Astrazeneca
• Bristol-Myers Squibb
• Castle Biosciences
• Daiichi Sankyo
• Damae Medical
• Dermtech
• F. Hoffmann-La Roche

Skin Cancer Diagnostics & Therapeutics Market Insights

Lucintel forecasts that non-melanoma is expected to witness higher growth over the forecast period due to growing the increasing cases of non-melanoma as these skin cancer starts in skin cells and a cancerous (malignant) growth is a group of cancer cells that can grow into and destroy nearby tissue. it can also spread (metastasize) to other parts of the body, but this is rare with non-melanoma skin cancer.

Within this market, therapeutic will remain the largest segment.

North America will remain the largest segment over the forecast period due to the growing prevalence and incidence of skin cancers in this region.

Features of the Global Skin Cancer Diagnostics & Therapeutics Market

Market Size Estimates: Skin cancer diagnostics & therapeutics market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Skin cancer diagnostics & therapeutics market size by cancer type, type, and region in terms of value ($B).

Regional Analysis: Skin cancer diagnostics & therapeutics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different cancer types, types, and regions for the skin cancer diagnostics & therapeutics market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the skin cancer diagnostics & therapeutics market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the skin cancer diagnostics & therapeutics market size?

Answer: The global skin cancer diagnostics & therapeutics market is expected to reach an estimated $18.1 billion by 2030.

Q.2 What is the growth forecast for skin cancer diagnostics & therapeutics market?

Answer: The global skin cancer diagnostics & therapeutics market is expected to grow with a cagr of 5.0% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the skin cancer diagnostics & therapeutics market?

Answer: The major drivers for this market are increasing government initiatives for early detection and skin cancer treatment, rising research and development activities for skin cancer diagnostics and therapeutics, and growing incidences and rising awareness of skin cancer globally.

Q4. What are the major segments for skin cancer diagnostics & therapeutics market?

Answer: The future of the skin cancer diagnostics & therapeutics market looks promising with opportunities in the diagnosis and therapeutic markets.

Q5. Who are the key skin cancer diagnostics & therapeutics market companies?

Answer: Some of the key skin cancer diagnostics & therapeutics companies are as follows:

• AB Science
• Abbott Laboratories
• Amgen
• AstraZeneca
• Bristol-Myers Squibb
• Castle Biosciences
• Daiichi Sankyo
• DAMAE Medical
• DermTech
• F. Hoffmann-La Roche

Q6. Which skin cancer diagnostics & therapeutics market segment will be the largest in future?

Answer: Lucintel forecasts that non-melanoma is expected to witness higher growth over the forecast period due to growing the increasing cases of non-melanoma as these skin cancer starts in skin cells and a cancerous (malignant) growth is a group of cancer cells that can grow into and destroy nearby tissue. it can also spread (metastasize) to other parts of the body, but this is rare with non-melanoma skin cancer.

Q7. In skin cancer diagnostics & therapeutics market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment over the forecast period due to the growing prevalence and incidence of skin cancers in this region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the skin cancer diagnostics & therapeutics market by cancer type (melanoma and non-melanoma), type (diagnosis, therapeutics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?